Miller, M.; Sahin, U.; Derhovanessian, E. et al.
IVAC MUTANOME: A first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanomaANNALS OF ONCOLOGY. Bd. 28. 2017
von Stebut, E.
Leishmaniasis Diagnosis and therapyHAUTARZT. Bd. 68. H. 7. 2017 S. 548-552
Behling, J.; Stege, H.; Schadmand-Fischer, S. et al.
Lethal Right Heart Failure in Pulmonary Artery Embolism, Pneumonitis and Myositis as a result of Therapy with PembrolizumabJOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. Bd. 15. 2017 S. 69-69
Schmidberger, H.; Rapp, M.; Ebersberger, A. et al.
Long term survival of patients after Ipilimumab and hypofractionated brain radiotherapy for brain metastases of malignant melanoma: sequence mattersJOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. Bd. 15. 2017 S. 11-11
Dietze-Schwonberg, K.; Kautz-Neu, K.; Roers, A. et al.
Mast cells: do they play a role in cutaneous leishmaniasis?EXPERIMENTAL DERMATOLOGY. Bd. 26. H. 3. 2017 S. E73-E74
Schepler, H.; Rietz, S.; Grabbe, S.
Melanocytic and epithelial Tumors at the Hand: Amputation versus ReconstructionJOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. Bd. 15. 2017 S. 174-174
Schloeder, J.; Berges, C.; Luessi, F. et al.
Modulating Treg resistance in autoimmune diseases: New treatment for Multiple Sclerosis patients improves T cell sensitivity towards Treg-mediated suppressionEUROPEAN JOURNAL OF IMMUNOLOGY. Bd. 47. 2017 S. 285-285
Stege, H.; Bradfisch, F.; Henning, B. et al.
Necrotizing leukocytoclastic Vasculitis under Therapy with Ipilimumab and Nivolumab in a Patient with malignant MelanomaJOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. Bd. 15. 2017 S. 72-72
Loquai, C.
New S3 Guidelines for malignant Melanoma - Consequences for the everyday clinical PracticeJOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. Bd. 15. 2017 S. 37-37
Behling, Juliane; Kaes, Joachim; Muenzel, Thomas et al.
New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanomaMELANOMA RESEARCH. Bd. 27. H. 2. 2017 S. 155-158